BOUCHERVILLE, QC, April 29, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: LSL.DB) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced today it will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference. Mr. Roberge, President and CEO, will make a presentation on May 5 at 10:30 EST, and will be available for one-on-one meetings throughout the conference.
Event: Date Location Presentation: | 2025 Bloom Burton & Co. Healthcare Investor Conference May 5 - 6, 2025 Metro Toronto Convention Center, Ontario May 5 - 10:30 EST |
A live and recorded webcast of the LSL Pharma presentation will be available on the "Information for Investors" section of LSL Pharma corporate website www.groupelslpharma.com or at the following link:
https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/7Ga7vvMLr2KgxFSJVAcWhM
For more information on the "2025 Bloom Burton & Co. Healthcare Investor Conference" or to register, please follow this link.
ABOUT THE CONFERENCE
The Bloom Burton & Co. Healthcare Investor Conference brings together American, Canadian and international investors interested in the latest developments in Canadian healthcare companies. Participants will have the opportunity to obtain up-to-date information on leading Canadian public and private companies, through presentations and private meetings.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and marketing of high-quality sterile ophthalmic pharmaceuticals, as well as cosmetic, pharmaceutical and natural health products in solid, semi-solid and liquid forms. For further information, please visit www.groupelslpharma.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed and does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Groupe LSL PHARMA INC.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/29/c0325.html
François Roberge, President and Chief Executive Officer, (514) 664-7700, E-mail : Investors@groupelslpharma.com